Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 1
1948 1
1949 3
1950 1
1951 3
1952 2
1953 3
1954 2
1955 4
1956 4
1957 4
1958 7
1959 2
1960 6
1961 4
1962 2
1963 2
1964 1
1965 2
1966 1
1968 2
1969 2
1970 5
1971 2
1972 4
1974 4
1975 4
1976 2
1977 10
1978 9
1979 7
1980 6
1981 5
1982 7
1983 5
1984 7
1985 10
1986 19
1987 16
1988 21
1989 16
1990 22
1991 12
1992 28
1993 17
1994 22
1995 25
1996 19
1997 27
1998 25
1999 24
2000 23
2001 28
2002 49
2003 29
2004 41
2005 39
2006 45
2007 55
2008 65
2009 69
2010 74
2011 71
2012 85
2013 107
2014 111
2015 142
2016 130
2017 140
2018 157
2019 133
2020 169
2021 158
2022 157
2023 155
2024 130
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,549 results

Results by year

Filters applied: . Clear all
Page 1
The latest on the role of LAMAs in asthma.
Cazzola M, Rogliani P, Matera MG. Cazzola M, et al. J Allergy Clin Immunol. 2020 Dec;146(6):1288-1291. doi: 10.1016/j.jaci.2020.06.014. Epub 2020 Jun 27. J Allergy Clin Immunol. 2020. PMID: 32603663 No abstract available.
Pharmacology and Therapeutics of Bronchodilators Revisited.
Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Matera MG, et al. Pharmacol Rev. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150. Pharmacol Rev. 2020. PMID: 31848208 Review.
This is currently achieved by use of fixed-dose combinations of inhaled long-acting beta (2)-adrenoceptor agonists (LABAs) and long-acting muscarinic acetylcholine receptor antagonists (LAMAs). Due to the distinct mechanisms of action of LAMAs and LABAs, the additiv …
This is currently achieved by use of fixed-dose combinations of inhaled long-acting beta (2)-adrenoceptor agonists (LABAs) and long-acting m …
The reality of LAMAs for adult asthmatic patients.
Luz MI, Aguiar R, Morais-Almeida M. Luz MI, et al. Expert Rev Respir Med. 2020 Nov;14(11):1087-1094. doi: 10.1080/17476348.2020.1794828. Epub 2020 Jul 20. Expert Rev Respir Med. 2020. PMID: 32687426
There are several studies completed or currently ongoing with the long-acting muscarinic antagonists (LAMAs) umeclidinium and glycopyrronium as an add-on asthma treatment. Adding a second bronchodilator with a different mechanism of action for the treatment of uncontrolled …
There are several studies completed or currently ongoing with the long-acting muscarinic antagonists (LAMAs) umeclidinium and glycopy …
[Vertigo].
Lamas G, Vidal C, Hervochon R. Lamas G, et al. Rev Prat. 2020 Dec;70(10):e343-e348. Rev Prat. 2020. PMID: 33739669 French. No abstract available.
Drugs for COPD.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Sep 7;62(1606):137-144. Med Lett Drugs Ther. 2020. PMID: 32960872 Review. No abstract available.
Muscarinic Receptor Antagonists.
Matera MG, Cazzola M. Matera MG, et al. Handb Exp Pharmacol. 2017;237:41-62. doi: 10.1007/164_2016_68. Handb Exp Pharmacol. 2017. PMID: 27787709 Review.
Further beneficial effects of SAMAs and LAMAs are seen when added to existing treatments, including LABAs, inhaled corticosteroids and phosphodiesterase 4 inhibitors. The importance of tiotropium bromide in the maintenance treatment of COPD, and likely in asthma, has spurr …
Further beneficial effects of SAMAs and LAMAs are seen when added to existing treatments, including LABAs, inhaled corticosteroids an …
Long-acting muscarinic antagonists.
Melani AS. Melani AS. Expert Rev Clin Pharmacol. 2015;8(4):479-501. doi: 10.1586/17512433.2015.1058154. Expert Rev Clin Pharmacol. 2015. PMID: 26109098 Review.
Inhaled bronchodilators are the mainstay of COPD pharmacological treatment. Long-acting muscarinic antagonists (LAMAs) are a major class of inhaled bronchodilators. Some LAMA/device systems with different characteristics and dosing schedules are currently approved for main …
Inhaled bronchodilators are the mainstay of COPD pharmacological treatment. Long-acting muscarinic antagonists (LAMAs) are a major cl …
Cough in children.
Lamas A, Ruiz de Valbuena M, Máiz L. Lamas A, et al. Arch Bronconeumol. 2014 Jul;50(7):294-300. doi: 10.1016/j.arbres.2013.09.011. Epub 2014 Feb 5. Arch Bronconeumol. 2014. PMID: 24507905 Review. English, Spanish.
2,549 results